Idhifa and Juvisync

• Generic Name: enasidenib
• Dosage Forms: tablet, film coated
• Other Brand Names: Idhifa, Idhifa

IDHIFA (enasidenib) targets a specific gene mutation called IDH2, which can affect your bone marrow. IDH2 mutation prevents young blood cells from developing into healthy adult blood cells, which can result in symptoms of acute myeloid leukemia.

IDHIFA is used to treat acute myeloid leukemia in adults with an IDH2 mutation.

IDHIFA is used when AML has come back or has not improved with prior treatment.

• Generic Name: simvastatin / sitagliptin
• Dosage Forms: tablet, film coated
• Other Brand Names: Juvisync

Juvisync contains a combination of simvastatin and sitagliptin. Simvastatin is an HMG CoA reductase inhibitor, or "statin." Simvastatin reduces levels of "bad" cholesterol (low-density lipoprotein, or LDL) and triglycerides in the blood, while increasing levels of "good" cholesterol (high-density lipoprotein, or HDL).

Sitagliptin is an oral diabetes medicine that helps control blood sugar levels. It works by regulating the levels of insulin your body produces after eating.

Juvisync is used in people with type 2 diabetes who also have high cholesterol or triglycerides (types of fat) in the blood. This medication is not for treating type 1 diabetes.

Juvisync is also used to lower the risk of stroke, heart attack, and other heart complications in people with diabetes, coronary heart disease, or other risk factors.

Juvisync may also be used for purposes not listed in this medication guide.